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Background: A crucial limitation of DNA vaccines is its weak 
immunogenicity, especially in terms of eliciting antibody re-
sponses in non-human primates or humans; therefore, it is 
essential to enhance immune responses to vaccination for 
the development of successful DNA vaccines for humans. 
Methods: Here, we approached this issue by evaluating in-
terleukin-7 (IL-7) as a genetic adjuvant in cynomolgus mon-
keys immunized with multigenic HCV DNA vaccine. Results: 
Codelivery of human IL-7 (hIL-7)-encoding DNA appeared to 
increase DNA vaccine-induced antibody responses specific 
for HCV E2 protein, which plays a critical role in protecting 
from HCV infection. HCV-specific T cell responses were also 
significantly enhanced by codelivery of hIL-7 DNA. Intere-
stingly, the augmentation of T cell responses by codelivery of 
hIL-7 DNA was shown to be due to the enhancement of both 
the breadth and magnitude of immune responses against 
dominant and subdominant epitopes. Conclusion:  Taken to-
gether, these findings suggest that the hIL-7-expressing 
plasmid serves as a promising vaccine adjuvant capable of 




At  least  170  million  people  worldwide  are  persistently  in-
fected with HCV, the most common reason for patients re-
quiring a liver transplant. An estimated 2.3 to 4.7 million peo-
ple  are  infected  every  year,  but  an  effective  vaccine  is  not 
yet available (1,2). Six different genotypes and a variety of 
quasispecies of HCV pose a major challenge for the develop-
m e n t  o f  a n  e f f e c t i v e  H C V  v a c c i n e .  H C V - s p e c i f i c  T  c e l l  r e -
sponses  have  been  shown  to  protect  HCV-recovered  chim-
panzees upon homologous, heterologous and cross-genotype 
HCV  rechallenge  (3,4).  A  recent  study  on  chimpanzees 
showed that vaccination with replication-defective adenoviral 
vector encoding HCV NS3-NS5B and booster vaccination with 
recombinant  DNA  plasmid  effectively  induced  protective  T 
cell immunity against challenge with a heterologous HCV (5). 
In  addition to T cell  response, neutralizing antibodies have 
been shown to be a key feature of effective vaccines against 
HCV infection (6,7). Thus, substantial effort has been focused 
on the induction of vigorous HCV-specific antibody as well 
a s  T  c e l l  i m m u n i t y .
    Multigenic  DNA  vaccination  is  one  of  the  most  effective 
ways to induce both antibody and broad T cell responses by 
intramuscular injection (8). DNA vaccines have used to gen-
erate  protective  immunity  against  various  pathogens  (9). 
Since the strength of the immune responses induced by DNA 
vaccines has been relatively weak compared with that of im-
mune  responses  induced  by  conventional  vaccines  such  as 
subunit  vaccines,  it  is  necessary  to  develop  novel  methods 
for circumventing this limitation, such as codelivery of novel 
cytokine adjuvants (10). Thus, immunostimulatory cytokines IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
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such  as  interleukin  (IL)-2,  IL-7,  IL-12,  IL-15  and  IL-18  have 
been  studied  as  genetic  adjuvants  (11).
    IL-7  is a glycoprotein of 25 kDa and secreted by thymic 
and intestinal epithelial cells, bone marrow stromal elements 
and  keratinocytes.  It  has  been  shown  to  be  an  essential 
growth factor for B and T lineage cells (12). Previous reports 
demonstrated that in vivo administration of IL-7 results in the 
increased numbers of B lineage cells and T cells with a pref-
erential  increase  in  CD8
＋  T  cells  (13,14).  It  has  also  been 
reported  that  IL-7  can  help  promote  the  proliferation  of  T 
cells (15) and enhance the lytic activity of CTLs and lympho-
kine-activated  killer  cells  (16).
  R e c e n t  r e s e a r c h  i n t o  t h e  b i o l o g y  o f  I L - 7  s u g g e s t s  t h a t  i t  
might serve as an effective vaccine adjuvant based on the fol-
lowing  reasons.  First,  IL-7  receptor-α is  expressed  on  the 
majority of resting, naive CD8
＋ T cells. IL-7 signaling recruits 
T cells specific for low-affinity antigens into the proliferative 
pool  in  lymphopenic  hosts  (17,18).  Additionally,  like  other 
common γ receptor chain (γc) cytokines, IL-7 prevents pro-
g r a m m e d  c e l l  d e a t h .  T h u s ,  I L - 7  t h e r a p y  m a y  d i m i n i s h  t h e  
magnitude of cell contraction following antigen-specific acti-
vation (19). At present, accumulating evidence implicates the 
effectiveness of recombinant IL-7 proteins or IL-7-expreesing 
plasmids as a positive immune regulator of vaccine-induced 
T cell responses. It has been reported that recombinant IL-7 
protein enhances the survival of Mycobacterium tuberculosis- 
infected  mice  by  the  activation  of  antigen-specific  effector 
CD8
＋ T cells (20). Furthermore, IL-7-expressing plasmids can 
enhance  vaccine-induced  CTL  and/or  Th2-type  immune  re-
sponses in mice injected with HSV-2 gD DNA vaccine (21). 
Co-formulation  of  IL-7-expressing  plasmids  in  the  HIV-1 
DermaVir nanoparticle significantly induced Gag-specific cen-
tral memory T cell responses but not effector memory T cell 
responses  (22).
    Although several reports state that administration of IL-7 as 
a  vaccine  adjuvant  can  enhance  antigen-specific  T  cell  re-
sponses in small animals, the role and action mechanism of 
IL-7  in  augmenting  antigen-spec i f i c  a n t i b o d y  a n d  T  c e l l  r e-
sponses, respectively, are still unclear, especially in non-hu-
man primates (21-23). Thus, it is highly worthwhile to per-
form a detailed analysis regarding the immunomodulatory ef-
fects of IL-7 as a novel DNA vaccine adjuvant. The role of 
IL-7 in non-human primate models may provide valuable in-
formation, because most of the previous reports showing the 
adjuvant  effects  of  IL-7  were  performed  in  mice  models 
(20,21,23,24).
    Here, we evaluated the immunomodulatory effects of hu-
man IL-7 (hIL-7)-expressing DNA in cynomolgus monkeys in-
jected with multigenic HCV DNA vaccine. We demonstrated 
for the first time that coinjection of hIL-7 DNA increases HCV 
DNA  vaccine-induced  antibody  as  well  as  broad  T  cell  re-
sponses  in  non-human  primates.
MATERIALS AND METHODS
Plasmids
HCV DNA vaccine contains three separate plasmids that ex-
press  the  core-NS2  (1∼191  a.a.  and  809∼968  a.a.),  E1E2 
(192∼729 a.a.) and NS34 (1,029∼1,971 a.a.). All HCV genes 
derived from the Korean genotype 1b strain (gHCV) were co-
don-optimized and synthesized by GenScript (NJ, USA) (25). 
These  synthesized  genes  were  inserted  into  pGX27,  which 
was fused with the signal sequences of human tissue plasmi-
nogen activator (tPa) (26). To construct pGX27-hIL-7, human 
IL-7  genes  were  codon-optimized  and  synthesized  by 
GenScript  and  then  cloned  into  pGX27  vector  (Fig.  1A).
Immunization
Twelve  naive  cynomolgus  monkeys  were  divided  into  3 
groups: 2 monkeys as the naive group; 5, group 1; and 5, 
group 2. A total 800μg of the following plasmid DNA was 
intramuscularly administrated with in vivo electroporation to 
each group of monkeys 6 times at the indicated months (Fig. 
1B). Group 1, pGX27-tpa-core-NS2 (200μg)＋pGX27-tpa-E1E2 
(200μg)＋pGX27-tpa-NS34 (200μg)＋pGX27-mock (200μg); 
Group  2,  pGX27-tpa-core-NS2  (200μg)＋pGX27-tpa-E1E2 
(200μg)＋pGX27-tpa-NS34 (200μg)＋pGX27-hIL-7 (200μg).
Synthetic HCV peptides
A  total of  156 overlapping peptides  having  20  amino  acids 
in  length  with  10  amino  acid  overlap  was  synthesized  by 
Peptron Inc. (Daejeon, S. Korea): 12 peptides for core (43∼
172 a.a.), 18 peptides for E1 (192∼381 a,a.), 31 peptides for 
E2 (384∼713 a.a.), 15 peptides for NS2 (809∼968 a.a.), 16 
for  NS3  protease  (1,029∼1,217  a.a.),  34  for  NS3  helicase 
(1,208∼1,647  a.a.)  and  30  peptides  for  NS4  (1,657∼1,966 
a.a.). All peptide sequences used for stimulation in the IFN-
γ ELISPOT assay were derived from the gHCV vaccine strain 
(genotype  1b)  (27).
IFN-γ ELISPOT assay
The ELISPOT assay was performed according to the manu-IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
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Figure 1. Schematic diagrams of 
DNA constructs and experimental 
schedules. (A) HCV DNA vaccines 
consisting of three separate plasmids 
encoding core-NS2, E1E2 and NS34 
were prepared as described in Ma-
terials and Methods. As a vaccine 
adjuvant, the gene encoding hIL-7 
was cloned into pGX27 vector. (B) 
HCV DNA vaccines with (group 2) 
or without (group 1) hIL-7 DNA 
were intramuscularly immunized 
with in vivo electroporation to each
group of monkeys six times at the 
indicated months.
facturer’s  instructions  in  the  IFN-γ ELISPOT  kit  with  mod-
ifications  (#CT126-PR20,  U-CyTech,  Netherlands).  In  brief, 
3×10
5  peripheral  blood  mononuclear  cells  (PBMCs)  from 
each monkey were plated onto 96-well plate in triplicate and 
were stimulated for 24 hours with the indicated peptide pool 
(1μg/ml per each peptide). The number of IFN-γ secreting 
cells was enumerated using an ELISPOT image analyzer (AID 
GmbH,  Germany).  Results  were  expressed  as  spot-forming 
cells  (SFCs)  per  10
6 P B M C s .
    To characterize peptides recognized by NS3-specific T cells 
in monkey PBMCs, the same numbers of PBMCs from each 
group 1 and group 2 monkey were pooled and then stimu-
lated with each of the peptides form NS3 protease (1,029∼
1,217 a.a.) and NS3 helicase (1,208∼1,647 a.a.) at a concen-
tration  of  10μg/ml.  Results  were  expressed  as  SFCs  per 
1×10
6 PBMCs. Cutoff values were set to have a higher SFCs 
than  those  of  control  (stimulated  with  irrelevant  synthetic 
p e p t i d e ,  E D R N N S H S E E Q N E K Q )  p l u s  3  s t a n d a r d  d e v i a t i o n s .
ELISA
Plasma samples were diluted 1/50 and used for the determi-
nation of anti-E2 IgG responses by standard ELISA technique 
a s  d e s c r i b e d  ( 6 , 2 5 , 2 8 ) .  P l a t e s  we r e  c o a t e d  w i t h  5 0μl  (2 
μg/ml) of hgh-E2t (384∼718 a.a., derived from the gHCV 
strain) (25). Color was generated by adding TMB substrate, 
and optical density was measured at 450 nm using an ELISA 
reader  (Bio-Tek  instruments).IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
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Statistical analysis
The difference in immune responses between groups was de-
termined with student’s T test. A p value of less than 0.05 
was  considered  statistically  significant.
RESULTS
Codelivery of hIL-7 enhances HCV-specific T cell re-
sponses in cynomolgus monkeys injected with multi-
genic HCV DNA vaccine
To  investigate  HCV-specific  immune  responses  induced  by 
multigenic HCV DNA vaccination in the presence or absence 
of hIL-7 DNA, twelve cynomolgus monkeys were divided into 
3 groups: 2 naive monkeys; 5 monkeys immunized with HCV 
DNA vaccine (group 1); and 5 monkeys immunized with HCV 
DNA vaccine plus hIL-7 DNA (group 2). The adjuvant effect 
of hIL-7 DNA on the induction of HCV DNA vaccine-induced 
T cell responses was evaluated by IFN-γ ELISPOT assays for 
HCV  core,  E1,  E2,  NS2,  NS3  and  NS4  proteins  using  cry-
o p r e s e r v e d  P B M C s  a t  f o u r  w e e k s  a f t e r  e a c h  i m m u n i z a t i o n  
(Fig. 1B). As expected, PBMCs from two naive monkeys dur-
i n g  t h i s  s t u d y  s h o w e d  n o  H C V - s p e c i f i c  I F N - γ production 
(Fig. 2A). Additionally, no significant T cell responses specific 
for  HCV  peptide  pools  were  detected  in  HCV  multigenic 
DNA-immunized  group  (group  1)  even  after  the  second 
vaccination. This observation is consistent with previous re-
ports that, in contrast to small animals such as mice, twice 
vaccination with DNA is unlikely to induce antibody and T 
cell immune responses in non-human primates (29). However, 
these HCV-specific T cell responses became detectable after 
the third vaccination and then continuously increased by re-
peated DNA vaccination until the sixth vaccination. Codeli-
very of hIL-7 DNA significantly increased the total HCV-spe-
cific T cell responses (p＜0.05; after the 4
th and the 6
th immu-
nization),  in  comparison  to  multigenic  HCV  DNA  alone. 
Moreover,  coimmunization  of  hIL-7  DNA  elicited  detectable 
T cell responses induced by HCV DNA vaccine even after the 
second vaccination, and increased vaccine-induced T cell re-
sponses against all vaccine antigens such as core-NS2, E1E2 
and NS34. This suggests that the hIL-7 induces earlier T cell 
responses elicited by codelivered HCV DNA vaccine and its 
a d j u v a n t  e f f e c t  i s  n o t  r e s t r i c t e d  t o  n a t u r e  o f  c e r t a i n  v i r a l  
antigens.
Increased T cell responses by codelivery of hIL-7 are 
due to enhancement of breadth and magnitude of 
immunity against dominant and subdominant epi-
topes
To determine the action mechanisms related to the enhance-
ment of T cell responses by codelivery of hIL-7 in multigenic 
HCV DNA vaccination, we compared the HCV DNA vaccine 
alone group (group 1) and the hIL-7 DNA codelivered group 
(group  2)  in  terms  of  the  breadth  and  magnitude  of  vac-
cine-induced T cell responses against each overlapping pep-
tide spanning the entire HCV NS3 region by IFN-γ ELISPOT 
assay at four weeks after the sixth immunization (Fig. 2B). 
I n  g r o u p  1 ,  w e  i d e n t i f i e d  a n t i g e n - s p e c i f i c  T  c e l l  r e s p o n s e s  
specific  for  four  (#1069,  #1078,  #1098  and  #1178)  and  two 
(#1228  and  #1588)  peptides  containing  NS3  protease-  and 
helicase-specific immunodominant epitopes, respectively. The 
T cell frequency was significantly increased in group 2 in re-
gards  to  these  immunodominant  epitopes  (#1069,  #1078, 
#1098, #1178 and #1588) except for the #1228 peptide, which 
indicates the codelivery effect of hIL-7 DNA on overall en-
hancement of antigen-specific T cell immunity specific to the 
immunodominant epitopes. Interestingly, codelivery of hIL-7 
DNA appeared to  induce  T  cell  responses  specific  to addi-
tional two (#1128 and #1138) and one (#1238) peptide from 
NS3 protease and helicase regions, respectively, which were 
not immunogenic in group 1. This indicates that codelivery 
of hIL-7 broadens DNA vaccine-induced T cell immunity by 
inducing  HCV-specific  T  cell  responses  specific  for  sub-
dominant epitopes. Taken together, we demonstrated that the 
e n h a n c e d  H C V  D N A  v a c c i n e - i n d u c e d  T  c e l l  r e s p o n s e s  o b -
served  in  group  2  are  due  to  the  increase  of  breadth  and 
magnitude of HCV-specific T cell responses specific to sub-
dominant  and  dominant  epitopes,  respectively.
Codelivery of hIL-7 increases anti-E2 antibody res-
ponses in cynomolgus monkeys injected with multi-
genic HCV DNA vaccine
T o  i n v e s t i g a t e  t h e  a d j u v a n t  e f f e c t  o f  h I L - 7  D N A  o n  t h e  i n-
duction of antibody responses by HCV DNA vaccine, the an-
ti-E2  antibody  response  was  measured  longitudinally  using 
the  plasma  from  naive  and  immunized  monkeys,  since  the 
titer of anti-E2 antibody is closely associated with protection 
from HCV infection (6). As expected, 2 naive monkeys did 
not show any anti-E2 antibody response through this study 
(Fig. 3). The anti-E2 antibody response became detectable af-
ter the second immunization in both group 1 and group 2, IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
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Figure 2. Effect of hIL-7 codelivery on multigenic HCV DNA vaccine-induced T cell responses. (A) For longitudinal analysis of HCV-specific
T cell responses in cynomolgus monkeys, IFN-γ ELISPOT assays using PBMCs stimulated with peptide pools encompassing core-NS2, E1E2
and NS34 were performed. To evaluate the T cell adjuvant effects of hIL-7 after the 4
th, 5
th and 6
th vaccination, the results were rearranged 
to show total HCV-specific T cell responses of each group. Responses are indicated as the number of IFN-γ-secreting cells per 1×10
6 PBMCs.
(B) At 4 weeks after the 6
th immunization, DNA vaccine-induced T cell responses against each 20-mer peptide spanning NS3 protease (1,029∼
1,217 a.a.) and NS3 helicase (1,208∼1,647 a.a.) were examined by IFN-γ ELISPOT assay. Responses are indicated as the number of IFN-γ
-secreting cells per 1×10
6 PBMCs.IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
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Figure 3. Effect of hIL-7 codelivery on HCV DNA vaccine-induced anti-E2 antibody responses. For longitudinal analysis of anti-E2 antibody response
in cynomolgus monkeys, anti-E2 total IgG responses were determined by ELISA. Antibody responses were expressed as absorbance at 450 nm
within the linear range.
w h i c h  w e r e  s i g n i f i c a n t l y  i n c r e a s e d  a f t e r  t h e  t h i r d  i m m u n i -
zation.  These  antibody  responses  were  continuously  in-
creased  by  additional  immunization  until  the  sixth  immuni-
zation. Codelivery of hIL-7 slightly enhanced vaccine-induced 
anti-E2 antibody responses after the third and the forth immu-
nization (p=0.35 and p=0.09, respectively), and the enhance-
ment  of  anti-E2  antibody  responses  by  codelivery  of  hIL-7 
DNA became statistically significant after the fifth immuniza-
tion (p＜0.05). However, the adjuvant effects of hIL-7 DNA 
were  diminished  after  the  sixth  immunization  (p=0.60).
DISCUSSION
We  demonstrated  for  the  first  time  that  codelivery  of  hIL-7 
DNA as a genetic adjuvant augmented multigenic DNA vac-
cine-induced T cell responses by enhancing both the magni-
tude and breadth of T cell responses in non-human primate 
models.  Additionally,  hIL-7  appeared  to  increase  DNA  vac-
cine-induced anti-E2 antibody response. Since IL-7 has been 
known to play a role in T cell homeostasis and survival, sev-
eral studies have examined the adjuvant effects of IL-7 on T 
cell  responses  in  small  animal  models  (22,23,30).  As  pre-
viously reported, IL-7 augments the number of tumor-reactive 
T  cells  responding  to  subdominant  tumor  antigens  in  tu-
mor-bearing hosts and lowers the threshold level for graft-ver-
sus-host disease (31). However, little is known about the ad-
juvant effect of IL-7 on the modulation of antibody as well 
as T cell responses in non-human primates. IL-7 is recognized 
as playing an important role in early B-cell development in-
cluding survival, proliferation and maturation (32). Continuous 
in  vivo  administration  of  recombinant  IL-7  significantly  in-
creased B-cell numbers by expanding pre-B cell compartment 
(33).  In  contrast  to  the  administration  of  recombinant  IL-7 
protein, the injection of IL-7-expressing plasmid induces sus-
tained in vivo expression of IL-7. Thus, it is possible that co-
administration  of  IL-7  DNA,  as  demonstrated  in  this  study, 
may possibly expand the pre-B-cell pool, which can further 
increase  naive  B-cell  population  that  can  differentiate  into 
plasmablasts  or  plasma  cells.
    There are accumulating results that large animals such as IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
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non-human primates are less immunogenic than small animal 
for  DNA  vaccine-induced  immunity,  which  may  be  an  in-
trinsic drawback of DNA vaccines. However, our results sug-
gest that repeated DNA vaccination up to six times may over-
come this limitation by eventually inducing strong antibody 
and T cell responses. Furthermore, we showed that codeliv-
ery of hIL-7 DNA augmented the breadth and magnitude of 
T  c e l l  r e s p o n s e s  a f t e r  s i x  r e p e a t e d  a d m i n i s t r a t i o n  o f  H C V  
DNA  vaccine.  It  was  previously  reported  that  both  broad 
HCV-specific T cell response and high titers of anti-E2 anti-
body response have been shown to play a critical role in pro-
tection against HCV infection (3-7). Together, our results may 
provide valuable information for designing an effective HCV 
DNA vaccine to prevent vaccinee from HCV infection or play 
a significant role in viral clearance in chronically-infected in-
dividuals  with  HCV.
ACKNOWLEDGEMENTS
We  are  grateful  to  Sang-Chun  Lee  and  Kwan-Seok  Lee  for 
their dedicated mice care and Choon-Mo Kang, Gang-Hyun 
Han  and  Choong-Yong  Kim  for  their  technical  support  in 
monkey  study.
    This work was supported by the Korea Research Founda-
tion Grant funded by the Korean Government (MEST) (KRF- 
2008-220-E00018) and by the World Class University program 
through the National Research Foundation of Korea funded 
by the Ministry of Education, Science and Technology (R31- 
2008-000-10105-0).
CONFLICTS OF INTEREST
The  authors  declare  no  financial  or  commercial  conflict  of 
interest.
REFERENCES
1. Kiyosawa K, Tanaka E, Sodeyama T, Furuta K, Usuda S, 
Yousuf M, Furuta S: Transition of antibody to hepatitis C 
virus  from  chronic  hepatitis  to  hepatocellular  carcinoma. 
Jpn  J  Cancer  Res  81;1089-1091,  1990
2. Alter  MJ,  Kruszon-Moran  D,  Nainan  OV,  McQuillan  GM, 
Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence 
of  hepatitis  C  virus  infection  in  the  United  States,  1988 
through  1994.  N  Engl  J  Med  341;556-562,  1999
3. Nascimbeni  M,  Mizukoshi  E,  Bosmann  M,  Major  ME, 
Mihalik K, Rice CM, Feinstone SM, Rehermann B: Kinetics 
of CD4＋ and CD8＋ memory T-cell responses during hep-
atitis C virus rechallenge of previously recovered chimpan-
zees.  J  Virol  77;4781-4793,  2003 
4 . L a n f o r d  R E ,  G u e r r a  B ,  C h a v e z  D ,  B i g g e r  C ,  B r a s k y  K M , 
Wang XH, Ray SC, Thomas DL: Cross-genotype immunity 
to  hepatitis  C  virus.  J  Virol  78;1575-1581,  2004 
5. Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole 
BB,  Pezzanera  M,  Tafi  R,  Arcuri  M,  Fattori  E,  Lahm  A, 
Luzzago  A,  Vitelli  A,  Colloca  S,  Cortese  R,  Nicosia  A:  A 
T-cell HCV vaccine eliciting effective immunity against het-
erologous virus challenge in chimpanzees. Nat Med 12;190- 
197,  2006
6. Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee 
CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince 
A M , Sun g  Y C : Sustained  E2 antib ody  re sp onse co rrelate s 
with reduced peak viremia after hepatitis C virus infection 
in  the  chimpanzee.  Hepatology  42;1429-1436,  2005
7. Forns  X,  Payette  PJ,  Ma  X,  Satterfield  W,  Eder  G, 
Mushahwar  IK,  Govindarajan  S,  Davis  HL,  Emerson  SU, 
Purcell RH, Bukh J: Vaccination of chimpanzees with plas-
mid DNA encoding the hepatitis C virus (HCV) envelope 
E2 protein modified the infection after challenge with ho-
mologous monoclonal HCV. Hepatology 32;618-625, 2000
8. Pertmer TM, Roberts TR, Haynes JR: Influenza virus nucleo-
protein-specific  immunoglobulin  G  subclass  and  cytokine 
responses elicited by DNA vaccination are dependent on 
the  route  of  vector  DNA  delivery.  J  Virol  70;6119-6125, 
1996
9. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, 
Robinson HL: DNA vaccines: protective immunizations by 
parenteral, mucosal, and gene-gun inoculations. Proc Natl 
Acad  Sci  U  S  A  90;11478-11482,  1993
10. Choi  SY,  Suh  YS,  Cho  JH,  Jin  HT,  Chang  J,  Sung  YC: 
Enhancement of DNA vaccine-induced immune responses 
by influenza virus NP gene. Immune Netw 9;169-178, 2009 
11. Barouch  DH,  Letvin  NL,  Seder  RA:  The  role  of  cytokine 
DNAs as vaccine adjuvants for optimizing cellular immune 
responses.  Immunol  Rev  202;266-274,  2004 
12. Appasamy PM: Biological and clinical implications of inter-
leukin-7 and lymphopoiesis. Cytokines Cell Mol Ther 5;25- 
39,  1999 
13. Faltynek CR, Wang S, Miller D, Young E, Tiberio L, Kross 
K,  Kelley  M,  Kloszewski  E:  Administration  of  human  re-
combinant IL-7 to normal and irradiated mice increases the 
numbers of lymphocytes and some immature cells of the 
myeloid  lineage.  J  Immunol  149;1276-1282,  1992
14. Komschlies KL, Gregorio TA, Gruys ME, Back TC, Faltynek 
CR, Wiltrout RH: Administration of recombinant human IL-7 
to mice alters the composition of B-lineage cells and T cell 
subsets, enhances T cell function, and induces regression 
of established metastases. J Immunol 152;5776-5784, 1994 
15. Morrissey  PJ,  Goodwin  RG,  Nordan  RP,  Anderson  D, 
Grabstein KH, Cosman D, Sims J, Lupton S, Acres B, Reed 
SG:  Recombinant  interleukin  7,  pre-B  cell  growth  factor, 
has costimulatory activity on purified mature T cells. J Exp 
Med  169;707-716,  1989
16. Alderson MR, Sassenfeld HM, Widmer MB: Interleukin 7 en-
hances cytolytic T lymphocyte generation and induces lym-
phokine-activated killer cells from human peripheral blood. IL-7 Codelivery Augments HCV DNA Vaccine-induced Immune Responses
Su-Hyung Park, et al.
205 IMMUNE NETWORK http://www.ksimm.or.kr Volume 10 Number 6 December 2010
J  Exp  Med  172;577-587,  1990 
17. Schluns  KS,  Kieper  WC,  Jameson  SC,  Lefrançois  L: 
Interleukin-7 mediates the homeostasis of naïve and memo-
ry  CD8  T  cells  in  vivo.  Nat  Immunol  1;426-432,  2000 
18. Tan  JT,  Dudl  E,  LeRoy  E,  Murray  R,  Sprent  J,  Weinberg 
KI,  Surh  CD:  IL-7  is  critical  for  homeostatic  proliferation 
and  survival  of  naive  T  cells.  Proc  Natl  Acad  Sci  U  S  A 
98;8732-8737,  2001 
19. Boise LH, Minn AJ, June CH, Lindsten T, Thompson CB: 
G ro w th factors can en hanc e ly m p h ocy te  survival w itho ut 
committing the cell to undergo cell division. Proc Natl Acad 
Sci  U  S  A  92;5491-5495,  1995
20. Maeurer MJ, Trinder P, Hommel G, Walter W, Freitag K, 
Atkins D, Störkel S: Interleukin-7 or interleukin-15 enhan-
ces survival of Mycobacterium tuberculosis-infected mice. 
Infect  Immun  68;2962-2970,  2000 
21. Sin JI, Kim J, Pachuk C, Weiner DB: Interleukin 7 can en-
hance antigen-specific cytotoxic-T-lymphocyte and/or Th2- 
type immune responses in vivo. Clin Diagn Lab Immunol 
7;751-758,  2000
2 2 .C a l a r o t a  S A ,  D a i  A ,  T r o c i o  J N ,  W e i n e r  D B ,  L o r i  F ,  
Lisziewicz  J:  IL-15  as  memory  T-cell  adjuvant  for  topical 
HIV-1  DermaVir  vaccine.  Vaccine  26;5188-5195,  2008 
23. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, 
Mackall  CL:  Adjuvant  IL-7  or  IL-15  overcomes  im-
munodominance and improves survival of the CD8＋ mem-
ory  cell  pool.  J  Clin  Invest  115;1177-1187,  2005
24. Geiselhart  LA,  Humphries  CA,  Gregorio  TA,  Mou  S, 
Subleski  J,  Komschlies  KL:  IL-7  administration  alters  the 
CD4:CD8 ratio, increases T cell numbers, and increases T 
c e l l  f u n c t i o n  i n  t h e  a b s e n c e  o f  a c t i v a t i o n .  J  I m m u n o l  
166;3019-3027,  2001 
25. Lee  KJ,  Suh  YA,  Cho  YG,  Cho  YS,  Ha  GW,  Chung  KH, 
Hwang JH, Yun YD, Lee DS, Kim CM, Sung YC: Hepatitis 
C  v iru s E 2  p ro te in  p u rifie d  fro m  m a m m a lia n  c e lls  is  fre-
quently  recognized  by  E2-specific  antibodies  in  patient 
sera.  J  Biol  Chem  272;30040-30046,  1997
26. Sheehan  JJ,  Tsirka  SE:  Fibrin-modifying  serine  proteases 
thrombin, tPA, and plasmin in ischemic stroke: a review. 
Glia  50;340-350,  2005
27. Youn JW, Park SH, Cho JH, Sung YC: Optimal induction 
of T-cell responses against hepatitis C virus E2 by antigen 
engineering in DNA immunization. J Virol 77;11596-11602, 
2003 
28. Park SH, Yang SH, Lee CG, Youn JW, Chang J, Sung YC: 
Efficient  induction  of  T  helper  1  CD4＋ T-cell responses 
to hepatitis C virus core and E2 by a DNA prime-adenovirus 
boost.  Vaccine  21;4555-4564,  2003
29. Park SH, Lee SR, Hyun BH, Kim BM, Sung YC: Codelivery 
of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell 
responses  but  not  humoral  responses  in  African  green 
monkeys.  Vaccine  26;3978-3983,  2008 
30. Ma A, Koka R, Burkett P: Diverse functions of IL-2, IL-15, 
and  IL-7  in  lymphoid  homeostasis.  Annu  Rev  Immunol 
24;657-679,  2006
3 1 .S i n h a  M L ,  F r y  T J ,  F o w l e r  D H ,  M i l l e r  G ,  M a c k a l l  C L :  
Interleukin  7  worsens  graft-versus-host  disease.  Blood 
100;2642-2649,  2002 
32. Milne CD, Paige CJ: IL-7: a key regulator of B lymphopo-
iesis.  Semin  Immunol  18;20-30,  2006 
33. Morrissey  PJ,  Conlon  P,  Charrier  K,  Braddy  S,  Alpert  A, 
Williams  D,  Namen  AE,  Mochizuki  D:  Administration  of 
IL-7 to normal mice stimulates B-lymphopoiesis and periph-
eral  lymphadenopathy.  J  Immunol  147;561-568,  1991